Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
JTO Clinical and Research Reports|June 9, 2021
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase InhibitorsPedro E N S Vasconcelos, Carol Gergis, Hollis Viray, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2017
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomesPaul A VanderLaan, Deepa Rangachari, Susan M Mockus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2018
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasSusan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, et al.
Lung Cancer (Amsterdam, Netherlands)|February 8, 2018
Tumor biomarker testing in non-small-cell lung cancer: A decade of changePaul A VanderLaan, Deepa Rangachari, Adnan Majid, et al.
Cancer Treatment Communications|November 25, 2015
Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practiceDeepa Rangachari, Paul A VanderLaan, Xiuning Le, et al.
Lung Cancer (Amsterdam, Netherlands)|February 17, 2015
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancersDeepa Rangachari, Norihiro Yamaguchi, Paul A VanderLaan, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2015
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitorsXiuning Le, Neelam V Desai, Adnan Majid, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2019
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical SamplesDeepa Rangachari, Ciric To, Jason E Shpilsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2024
Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS OutcomesCatherine B Meador, Subba R Digumarthy, Beow Y Yeap, et al.
Lung Cancer (Amsterdam, Netherlands)|September 8, 2022
Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancerDaniel Sentana-Lledo, Hollis Viray, Andrew J Piper-Vallillo, et al.
Pageof 7